Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetically modified viruses: vaccines by design.

J R Stephenson1

  • 1Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, UK. j.stephenson@1sthm.ac.uk

Current Pharmaceutical Biotechnology
|August 3, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of recombinant antigens as diagnostic reagents in enzyme-linked immunosorbent assays.

Methods in molecular medicine·2011
Same author

Tick-borne encephalitis virus - a review of an emerging zoonosis.

The Journal of general virology·2009
Same author

Serum levels of interleukin 6 in recently hospitalized tick-borne encephalitis patients correlate with age, but not with disease outcome.

Clinical and experimental immunology·2008
Same author

Combined prime-boost vaccination against tick-borne encephalitis (TBE) using a recombinant vaccinia virus and a bacterial plasmid both expressing TBE virus non-structural NS1 protein.

BMC microbiology·2005
Same author

A synthetic peptide based on the NS1 non-structural protein of tick-borne encephalitis virus induces a protective immune response against fatal encephalitis in an experimental animal model.

Virus research·2005
Same author

Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus.

Virus genes·2004

New vaccine technologies using genetically modified viruses offer hope for diseases like malaria and AIDS, where traditional methods have failed. This approach modifies safe viruses to express proteins from other pathogens, creating novel vaccine candidates.

Area of Science:

  • Vaccinology and Virology
  • Infectious Disease Research

Background:

  • Vaccination is a highly successful public health intervention, eradicating smallpox and nearing polio eradication.
  • Conventional vaccine development (attenuation, inactivation, purification) has limitations for diseases like malaria, AIDS, and viral hepatitis.
  • New technologies are essential to address infectious diseases where traditional vaccines are ineffective.

Purpose of the Study:

  • To review the development of genetically modified viruses as novel vaccine vectors.
  • To compare the advantages and disadvantages of these new vaccine technologies.
  • To summarize existing literature on the use of genetically modified viruses in experimental vaccines.

Main Methods:

  • Reviewing scientific literature on vaccine development and genetically modified viruses.

Related Experiment Videos

  • Analyzing the process of modifying safe vaccine viruses (e.g., vaccinia, adenovirus) with genes from target pathogens.
  • Comparing the efficacy and safety profiles of different novel vaccine vector approaches.

    • Main Results:

    • Genetically modified viruses represent a promising new strategy for vaccine development.
    • This technology allows for the expression of immunogenic proteins from challenging pathogens.
    • The review covers the generation and application of these novel vaccine vectors.

    Conclusions:

    • Genetically modified viruses offer a potentially powerful approach to developing vaccines against diseases that have eluded traditional methods.
    • Further research and development are needed to fully realize the potential of these novel vaccine vectors.
    • This technology holds promise for tackling major global health challenges such as malaria and AIDS.